Background: It is not clear if long‐term antithrombotic treatment has a beneficial effect on the
incidence of thromboembolism in chronic heart failure (CHF). The HELAS study (Heart …

In patients with heart failure the risk of systemic thromboembolism and the benefit of
anticoagulation are uncertain. To assess the incidence of systemic thromboembolism and …

Background—In patients with heart failure, rates of clinically apparent stroke range from
1.3% to 3.5% per year. Little is known about the incidence and risk factors in the absence of …

Background The incidence of thromboembolism and the benefit of anticoagulation in
congestive heart failure are controversial. Methods and results The data base provided by …

BACKGROUND: The role of anticoagulation in patients with chronic heart failure has long
been an area of interest and controversy. Traditionally the goal of anticoagulation has been …

Background: Cardiac failure is associated with both stroke of presumed cardioembolic origin
and a high mortality rate. Warfarin is used frequently in patients with reduced cardiac left …

The purpose of this review is to determine the risk of vascular occlusion due to either in situ
thrombosis or thromboembolism in patients with major ventricular dysfunction with or without …

BACKGROUND: Heart failure is commonly associated with vascular disease and a high rate
of athero-thrombotic events, but the risks and benefits of antithrombotic therapy are …

Background—Chronic heart failure remains a major cause of mortality and morbidity. The
role of antithrombotic therapy in patients with chronic heart failure has long been debated …

Chronic heart failure (HF) with either reduced or preserved ejection fraction is common and
remains an extremely serious disorder with a high mortality and morbidity. Many …